Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a type of prostate cancer called adenocarcinoma, confirmed by a tissue or cell sample, that is not the small cell type.
• People whose prostate cancer continued to grow or spread while they were on hormone-reducing therapy (or after surgical removal of both testicles), within 6 months before the screening visit.
• People who currently have evidence that their cancer has spread to other parts of the body (metastatic disease).
• People who have already been treated with 1 or 2 specific hormone-blocking drugs (called androgen receptor pathway inhibitors) and whose cancer progressed during or after that treatment.
• People taking bone-strengthening medications (such as bisphosphonates or denosumab) must have been on a stable dose for at least 4 weeks before joining the trial.
• People with a general health and activity level rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity), assessed within 10 days before joining.
• People who have previously been treated with a type of drug called a PARP inhibitor, if that was recommended under local treatment guidelines, or who were assessed by the doctor as not suitable to receive one.

Who may not be able to join:

• People who have a history of, or currently have, a non-infectious lung condition called interstitial lung disease or pneumonitis that needed steroid treatment, or where this condition is suspected.
• People with serious breathing difficulties caused by ongoing lung illness.
• People with uncontrolled or significant heart or blood vessel disease.
• People with a history of problems with the pituitary gland.
• People with poorly controlled diabetes.
• People with a history of, or current, adrenal insufficiency (a condition where the adrenal glands do not produce enough hormones, such as Addison's disease).
• People who have previously received a chemotherapy drug from the taxane family specifically for advanced prostate cancer that no longer responds to hormone therapy.
• People who are on long-term steroid medication at a dose higher than 10 mg of prednisone (or equivalent) per day — low-dose inhaled steroids for asthma or lung disease, skin creams for mild skin conditions, and joint injections are generally exceptions (confirm with trial site).
• People who have had radiotherapy within 2 weeks before starting the study treatment, or who still have side effects from radiation that require steroid treatment.
• People who have another cancer that is currently growing or has needed active treatment within the past 3 years.
• People with cancer that has spread to the brain or the lining around the brain or spinal cord.
• People who have an active autoimmune disease that has needed systemic (whole-body) treatment within the past 2 years.
• People who have had an organ or tissue transplant from another person.

Important: Always verify eligibility with the trial site directly before applying.